Health Care Analysis

, Volume 9, Issue 2, pp 187–211 | Cite as

The Ethics of Aggregation and Hormone Replacement Therapy

  • Anne Drapkin Lyerly
  • Evan R. Myers
  • Ruth R. Faden

Abstract

The use of aggregated quality of life estimatesin the formation of public policy and practiceguidelines raises concerns about the moralrelevance of variability in values inpreferences for health care. This variabilitymay reflect unique and deeply held beliefs thatmay be lost when averaged with the preferencesof other individuals. Feminist moral theorieswhich argue for attention to context andparticularity underline the importance ofascertaining the extent to which differences inpreferences for health states revealinformation which is morally relevant toclinicians and policymakers. To facilitatethese considerations, we present an empiricalstudy of preferences for the timing andoccurrence of health states associated withhormone replacement therapy (HRT). Sixteenwomen between the ages of 45 and 55 wereenrolled in this pilot study. Theirpreferences regarding five health statesassociated with HRT (menopausal symptoms, sideeffects of HRT, breast cancer, myocardialinfarction, and osteoporosis) were assessed inquantitative terms known as utilities. Twostandard methods, the visual analog scale (VAS) and the standard gamble (SG), were used toassess utility and time preference (calculatedas a discount rate). The wide variability ofresponses underlines the importance oftailoring health care to individual women'spreferences. Policy guidelines whichincorporate utility analysis must recognize thenormative limitations of aggregatedpreferences, and the moral relevance ofindividual conceptions of health.

cost-effective analysis decision analysis distributive justice feminist theory hormone replacement therapy menopause patient preferences time preference utility women 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bastian, L.A., Couchman, G.M., Rimer, B.K., McBride, C.M., Feaganes, J.R. and Siegner, I.C. (1997) Perceptions of Menopausal Stage and Patterns of Hormone Replacement Therapy Use. Journal of Women's Health 6, 467-475.Google Scholar
  2. Benhabib, S. (1986) The Generalized and the Concrete Other: The Kohlberg-Gilligan Controversy and Feminist Theory. Praxis International 5, 402-424.Google Scholar
  3. Black, W.C., Nease, R.F. and Toteston, A. (1995) Perceptions of Breast Cancer Risk and Screening Effectiveness in Women Younger than 50 Years of Age. Journal of the National Cancer Institute 87, 720-731.Google Scholar
  4. Canadian Task Force on the Periodic Health Examination (1994) Canadian Guide to Clinical Preventive Health Care (pp. 620-631). Ottowa: Canada Communication Group.Google Scholar
  5. Chapman, G.B. and Elstein, A. (1995) Valuing the Future: Temporal Discounting of Health and Money. Medical Decision Making 15, 373-386.Google Scholar
  6. Clancy, C.M. and Eisenberg, J.M. (1998) Outcomes Research: Measuring the End Results of Health Care. Science 282, 245-246.Google Scholar
  7. Clinical Synthesis Panel on HRT (1999) Hormone Replacement Therapy: Clinical Synthesis Panel on HRT. Lancet 354, 152-155.Google Scholar
  8. Col, N.F., Eckman, M.H., Karas, R.H., Paukner, S.G., Goldberg, R.J., Ross, E.M., Orr, R.K. and Wong, J.B. (1997) Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women. Journal of the American Medical Association 277, 1140-1147.Google Scholar
  9. Cowen, M.E., Miles, B.J., Cahill, D.F., Giesler, R.B., Beck, J.R. and Kattan, M.W. (1998) The Danger of Applying Group-Level Utilities in Decision Analyses of the Treatment of Localized Prostate Cancer in Individual Patients. Medical Decision Making 18, 376-380.Google Scholar
  10. Daly, E., Gray, A., Barlow, D., McPherson, K., Roche, M. and Vessey, M. (1993) Measuring the Impact of Menopausal Symptoms on Quality of Life. British Medical Journal 307, 836-840.Google Scholar
  11. Eddy, D. (1991) Rationing by Patient Choice. Journal of the American Medical Association 265, 107.Google Scholar
  12. Gilligan, C. (1977) In a Different Voice: Women's Conceptions of Self and Morality. Harvard Educational Review 47(4), 67-103.Google Scholar
  13. Gilligan, C. (1984) In a Different Voice: Psychological Theory and Women's Development. Cambridge, MA: Harvard University Press.Google Scholar
  14. Gilligan, C. (1987) Moral Orientation and Moral Development. In: E.F. Kittay and D.T. Meyers (Eds.), Women and Moral Theory (pp. 19-33). Savage, MD: Rowman and Littlefield Publishers.Google Scholar
  15. Grodstein, F., Stampfer, M.J., Colditz, G.A., Willett, W.C., Rosner, B., Speizer, F.E. and Hennekens, C.H. (1996) Postmenopausal Estrogen and Progesterone and Risk of Cardiovascular Disease. New England Journal of Medicine 335, 453-461.Google Scholar
  16. Gold, M.R., Siegel, J.E., Russell, L.B. and Weinstein, M.C. (1996) Cost Effectiveness in Health and Medicine. New York: Oxford University Press.Google Scholar
  17. Haas, J. (1998) The Cost of Being a Woman. New England Journal of Medicine 338, 1694-1695.Google Scholar
  18. Hulley, S., Grady, D., Bust, T., Furberg, C., Herrington, D. and Vittinghoff, E. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group (1998) Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Journal of the American Medical Association 280, 605-613.Google Scholar
  19. Jaggar, A. (1989) Love and Knowledge: Emotion in Feminist Epistemology. Inquiry 32, 151-177.Google Scholar
  20. Kittay, E.F. and Meyers, D.T. (1987) Introduction, Women and Moral Theory (pp. 3-16). Savage, MD: Rowman and Littlefield Publishers.Google Scholar
  21. Lenert, L.A. and Soetikno R.M. (1997) Automated Computer Interviews to Elicit Utilities: Potential Application in the Treatment of Deep Venous Thrombosis. Journal of the American Medical Association 4, 49-56.Google Scholar
  22. Lock, M. (1998) Anomalous Women and Political Strategies. In S. Sherwin (Ed.), The Politics of Women's Health: Exploring Agency and Autonomy (pp. 178-204). Philadelphia: Temple University Press.Google Scholar
  23. Love, S. (1995) Dr Susan Love's Breast Book. New York: Addison-Wesley Publishing Company.Google Scholar
  24. MacPherson, K.L. (1981) Menopause as Disease: The Social Construction of a Metaphor. Advances in Nursing Science 3(2), 95-113.Google Scholar
  25. Mahowald, M.B. (1996) On Treatment of Myopia: Feminist Standpoint Theory and Bioethics. In: Susan Wolf (Ed.), Feminism and Bioethics (pp. 95-115). New York: Oxford University Press.Google Scholar
  26. Mahowald, M.B. (2000) Genes, Woman, Equality. New York: Oxford University Press.Google Scholar
  27. Menzel, P., Gold, M., Nord, E., Pinto-Prades, J., Richardson, J. and Ubel, P. (1999) Toward a Broader View of Values in Cost-Effectiveness Analysis of Health. Hastings Center Report 29(3), 7-15.Google Scholar
  28. Menzel, P. (1999) How Should What Economists Call “Social Values” Be Measured? Journal of Ethics 3, 249-273.Google Scholar
  29. Newton, K.M., LaCroix, A., Leville, S.G., Rutter, C., Deenan, N. and Anderson, L. (1997) Women's Beliefs and Decisions about Hormone Replacement Therapy Journal of Women's Health 6, 459-465.Google Scholar
  30. Nord, E. (1999) Cost-Value Analysis in Health Care. Cambridge: Cambridge University Press.Google Scholar
  31. Posner, J. (1979) It's All in Your Head: Feminist and Medical Models of Menopause (Strange Bedfellows). Sex Roles 5, 179-190.Google Scholar
  32. Powers, M. and Faden, R. (2000) Inequalities in Health, Inequalities in Health Care: Four Generations of Discussion about Justice and Cost-Effectiveness Analysis. Kennedy Institute of Ethics Journal 10, 109-127.Google Scholar
  33. Rabin, D.R. (1998) Understanding Why Women Won't Take HRT. Contemporary OB/GYN (pp. 133-141).Google Scholar
  34. Rawls, J. (1971) A Theory of Justice. Cambridge, MA: Harvard University Press.Google Scholar
  35. Redelmeier, D.A. and Heller, D.N. (1993) Time Preference in Medical Decision Making and Cost-Effectiveness Analysis. Medical Decision Making 13, 212-217.Google Scholar
  36. Rutten-Van Molken, M., Bakker, C.H., van Doorslaer, E. and van der Linden, S. (1995) Methodologic Issues of Patient Utility Measurement: Experience From Two Clinical Trials. Medical Care 33, 922-937.Google Scholar
  37. Schairer, C., Lubin, J., Troisi, R., Sturgeon, S., Brinton, L. and Hoover, R. (2000) Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk. Journal of the American Medical Association 283, 485-491.Google Scholar
  38. Sox, H., Blatt, M.A., Higgins, M.C. and Marton, K.I. (1986) Medical Decision Making. Boston: Butterworths.Google Scholar
  39. Spelman, E. (1988) Inessential Woman: Problems of Exclusion in Feminist Thought. Boston: Beacon Press.Google Scholar
  40. Sumner, W., Nease, R. and Littenberg, B. (1991) U-titer: a Utility Assessment Tool. Proceedings of the 15th Annual Symposium on Computer Applications in Medical Care (pp. 701-705). New York: McGraw-Hill.Google Scholar
  41. Tosteson, A. and Weinstein, M. (1991) Cost Effectiveness of Hormone Replacement Therapy After Menopause. Baillieres Clinics of Obstetrics and Gynecology 5, 943-959.Google Scholar
  42. Tosteson, A., Gabriel, S.E., Kneeland, T.S., Moncur, M.M., Manganiello, P.D., Schiff, I., Ettinger, B. and Melton, L.J. (2000) Has the Impact of Hormone Replacement Therapy on Health-Related Quality of Life been Undervalued? Journal of Women's Health and Gender Based Medicine 9, 119-130.Google Scholar
  43. Ubel, P.A. (2000) Pricing Life: Why it's Time for Health Care Rationing. Cambridge, MA: MIT Press.Google Scholar
  44. U.S. Preventive Services Task Force (1996) Guide to Clinical Preventive Services. 2nd edn (pp. 829-843). Baltimore: Williams and Wilkins.Google Scholar
  45. Weinstein, M. and Tosteson, A. (1990) Cost Effectiveness of Hormone Replacement Annals of the New York Academy of Sciences 592, 162-172.Google Scholar
  46. Wicklund, I., Karlberg, J. and Mattsson, L. (1993) Quality of Life of Postmenopausal Women on a Regimen of Transdermal Estradiol Therapy: a Double-Blind Placebo-Controlled Study. American Journal of Obstetrics and Gynecology 168, 824-830.Google Scholar
  47. Wolf, S. (1996) Feminism and Bioethics: Beyond Reproduction. New York: Oxford University Press.Google Scholar
  48. Young, I.M. (1990) Justice and the Politics of Difference. Princeton, NJ: Princeton University Press.Google Scholar
  49. Zug, K.A., Littenberg, B., Baughman, R., Kneeland, T., Nease, R., Sumner, W., O'Connor, G.T., Jones, R., Morrison, E. and Cimis, R. (1995) Assessing the Preferences of Patients with Psoriasis: A Quantitative, Utility Approach Archives of Dermatology 131, 561-568.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Anne Drapkin Lyerly
    • 1
  • Evan R. Myers
    • 3
  • Ruth R. Faden
    • 1
  1. 1.The Bioethics Institute, Johns Hopkins University and The Kennedy Institute of EthicsGeorgetown UniversityUSA
  2. 2.The Bioethics InstituteJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of Obstetrics and GynecologyDuke UniversityUSA

Personalised recommendations